News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,330 Results
Type
Article (39004)
Company Profile (277)
Press Release (645049)
Section
Business (203847)
Career Advice (1987)
Deals (35360)
Drug Delivery (85)
Drug Development (80782)
Employer Resources (168)
FDA (16085)
Job Trends (14802)
News (344506)
Policy (32431)
Tag
Academia (2530)
Alliances (49054)
Alzheimer's disease (1219)
Approvals (16007)
Artificial intelligence (124)
Bankruptcy (352)
Best Places to Work (11505)
Biotechnology (196)
Breast cancer (114)
Cancer (995)
Cardiovascular disease (83)
Career advice (1657)
Cell therapy (213)
Clinical research (64048)
Collaboration (346)
Compensation (183)
COVID-19 (2523)
C-suite (86)
Data (977)
Diabetes (145)
Diagnostics (6116)
Earnings (84534)
Employer resources (146)
Events (109199)
Executive appointments (267)
FDA (16558)
Funding (309)
Gene therapy (159)
GLP-1 (569)
Government (4321)
Healthcare (18659)
Infectious disease (2604)
Inflammatory bowel disease (103)
Interviews (308)
IPO (16279)
Job creations (3624)
Job search strategy (1415)
Layoffs (410)
Legal (7851)
Lung cancer (159)
Manufacturing (160)
Medical device (13158)
Medtech (13163)
Mergers & acquisitions (19126)
Metabolic disorders (381)
Neuroscience (1470)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1336)
Obesity (223)
Opinion (177)
Patents (96)
People (56174)
Phase I (19890)
Phase II (28203)
Phase III (21044)
Pipeline (328)
Postmarket research (2553)
Preclinical (8455)
Radiopharmaceuticals (234)
Rare diseases (196)
Real estate (5888)
Regulatory (21468)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1186)
Startups (3560)
United States (12481)
Vaccines (544)
Weight loss (164)
Date
Today (131)
Last 7 days (953)
Last 30 days (3329)
Last 365 days (35345)
2024 (31425)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54088)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37554)
2014 (31320)
2013 (26345)
2012 (28572)
2011 (29264)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37068)
Australia (6043)
California (3004)
Canada (1216)
China (234)
Colorado (130)
Connecticut (137)
Europe (79347)
Florida (418)
Georgia (107)
Illinois (328)
Indiana (188)
Kansas (96)
Maryland (549)
Massachusetts (2413)
Michigan (149)
Minnesota (260)
New Jersey (884)
New York (891)
North Carolina (676)
Northern California (1336)
Ohio (129)
Pennsylvania (790)
South America (1091)
Southern California (1186)
Texas (414)
Utah (84)
Washington State (338)
684,330 Results for "nitto denko avecia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Nitto Acquires Bend Labs, Inc. in the United States
Nitto Denko Corporation (headquarter: Osaka, Japan, President: Hideo Takasaki, hereafter Nitto) (TOKYO:6988) and Bend Labs, Inc. (US, Co-CEO: Jared Jonas, Colton Ottley, hereafter “Bend”) have agreed on Nitto’s acquisition of Bend.
June 1, 2022
·
2 min read
Nitto Strengthens Oligonucleotide Therapeutic Manufacturing Business
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc.
March 31, 2021
·
3 min read
Business
New President Appointed for Nitto Avecia Inc.
Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.
August 3, 2018
·
2 min read
Business
n-Lorem Foundation Announces Partnership with Nitto Avecia to Strengthen Development of Personalized Medicines for Patients with Ultra-Rare Diseases
n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients with ultra-rare diseases, today announced a new partnership with Nitto Avecia, the world’s largest oligonucleotide therapeutics manufacturer.
June 16, 2021
·
4 min read
Genetown
Nitto Denko Avecia Inc. Announces Multiple Oligonucleotide Expansions
November 14, 2016
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Lipid Nanoparticles (LNPs) CDMO Market to Reach USD 518.2 Million with a CAGR of 14.10% from 2024-2031
Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.
April 23, 2024
·
7 min read
Biotech Bay
Biotech Startup Announces R&D Collaboration With Major Japanese Drug Delivery Company
CAGE Bio Inc. announced a research and development agreement with Nitto Denko Corporation for a transdermal formulation of undisclosed molecules.
July 7, 2020
·
2 min read
Deals
Nitto Denko Avecia Inc. Acquires The Businesses Of Irvine Pharmaceutical Services, Inc. & Avrio Biopharmaceuticals
October 12, 2016
·
2 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
1 of 68,433
Next
